Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

14 Jan 2016

Abstract excerpt

Cisplatin was the first metal-based therapeutic agent approved for the treatment of human cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized the parent complex [Ru(phen)2(PIP)](2+) (1) to develop three Ru(II) complexes (2-4) with different positional modifications. These compounds exhibited similar or superior cytotoxicities compared to cisplatin in HeLa, A549 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferrocene Chemistry and Applications
Share to Metal complexes synthesis and properties

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26763798
DOI: 10.1038/srep19449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor CellsPMID 26763798Read ↗

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biologySemantic proximity Read ↗

ROS-mediated antitumor activity, apoptosis, and molecular docking studies of platinum (II) coordination complexes bearing 2-(diphenylphosphino)pyridine ligandSemantic proximity Read ↗

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer TherapySemantic proximity Read ↗

A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complexSemantic proximity Read ↗

Metallodrugs: an approach against invasion and metastasis in cancer treatmentSemantic proximity Read ↗

Platinum Complexes as Anticancer AgentsSemantic proximity Read ↗

Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP InhibitionSemantic proximity Read ↗

Copper(II) Phenanthroline-Based Complexes as Potential AntiCancer Drugs: A Walkthrough on the Mechanisms of ActionSemantic proximity Read ↗

Progress of Metal‐Based Anticancer Chemotherapeutic Agents in Last two Decades and their Comprehensive Biological (DNA/RNA Binding, Cleavage and Cytotoxicity Activity) StudiesSemantic proximity Read ↗

Third row transition metals for the treatment of cancerSemantic proximity Read ↗

DNA binding, antitubercular, antibacterial and anticancer studies of newly designed piano-stool ruthenium( ii ) complexesSemantic proximity Read ↗

Fresh Platinum Complexes with Promising Antitumor ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.